Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence ...
Thousands across the Mid-Atlantic and New England regions are without power Monday morning as a powerful Nor' easter batters ...
The latest entry in the GT series combines updated activity tracking and excellent battery life alongside a premium build.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback